证券代码：688046 证券简称：药康生物 公告编号：2024-048 江苏集萃药康生物科技股份有限公司 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 69 | | --- | --- | | 普通股股东人数 | 69 | | 2、出席会议的股东所持有的表决权数量 | 231,956,148 | | 普通股股东所持有表决权数量 | 231,956,148 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 56.7854 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 56.7854 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东会议由公司董事会召集，董事长高翔先生主持，采用现场和网络 ...

江苏世纪同仁律师事务所 关于江苏集萃药康生物科技股份有限公司 2024年第一次临时股东大会的 法 律 意 见 书 江苏集萃药康生物科技股份有限公司: 根据《中华人民共和国公司法》(以下简称"《公司法》")、《中华人民 共和国证券法》《上市公司股东大会规则》和《上海证券交易所科创板上市公司 自律监管指引第1 号 -- 规范运作》等法律、法规和规范性文件以及《公司章程》 的规定,本所受公司委托,指派本所律师出席公司 2024年第一次临时股东大会, 并就本次股东大会的召集、召开程序、出席会议人员资格、召集人资格、表决程 序以及表决结果的合法有效性等事项出具法律意见。 为出具本法律意见书,本所律师对本次股东大会所涉及的有关事项进行了审 查,查阅了相关会议文件,并对有关问题进行了必要的核查和验证。 本所律师同意将本法律意见书随公司本次股东大会决议一并公告,并依法对 本法律意见书承担相应的责任。 经查,公司本次股东大会的通知时间符合《公司法》《上市公司股东大会规 则》和《公司章程》的规定。 2、本次股东大会的投票方式 本次股东大会采取现场投票与网络投票相结合的方式召开。 经查,本次股东大会已按照会议通知通过上海证券交易所 ...

江苏集萃药康生物科技股份有限公司 关于持股 5%以上股东持股比例降至 5%以下的权益变 动提示性公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688046 证券简称：药康生物 公告编号：2024-047 本次权益变动属于股份减持，不触及要约收购。 本次权益变动后，江苏集萃药康生物科技股份有限公司（以下简称"公 司"）股东青岛国药大创投资合伙企业（有限合伙）（以下简称"青岛国药"）持 有公司股份从21,388,190股减少至20,500,000股，占公司总股本比例从5.22%减少 至5.00%。 本次权益变动为公司持股5%以上非第一大股东股份变动，不会导致公司 控股股东及实际控制人发生变化。 公司于 2024 年 9 月 24 日收到公司股东青岛国药出具的《简式权益变动 报告书》，现将其权益变动情况公告如下： 一、本次权益变动基本情况 （一）信息披露义务人的基本情况 1、青岛国药基本情况 | 企业名称 | 青岛国药大创投资合伙企业（有限合伙） | | --- | --- | | 注册地 ...

上市公司名称：江苏集萃药康生物科技股份有限公司 股票简称：药康生物 股票代码：688046 股票上市地点：上海证券交易所 江苏集萃药康生物科技股份有限公司 简式权益变动报告书 信息披露义务人：青岛国药大创投资合伙企业（有限合伙） 住所：山东省青岛市高新区华中路66号基金谷1号楼103-10室 通讯地址：上海市浦东新区东园路189号20楼 股份变动性质：减持股份至5% 签署日期：2024年9月24日 1 信息披露义务人声明 一、本报告书依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证券的公司 信息披露内容与格式准则第15号——权益变动报告书》及相关的法律、法规和 规范性文件编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不 违反信息披露义务人公司章程或内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发 行证券的公司信息披露内容与格式准则第15号——权益变动报告书》的规定， 本报告书已全面披露信息披露义务人在江苏集萃药康生物科技股份有限公司中 拥有权益的股份变动情况。 四 ...

华泰联合证券有限责任公司 关于江苏集萃药康生物科技股份有限公司 2024 年半年度持续督导跟踪报告 保荐机构名称：华泰联合证券有限责任公司 被保荐公司简称：江苏集萃药康生物科技股 份有限公司 保荐代表人姓名：季李华 联系电话：010-56839300 保荐代表人姓名：洪捷超 联系电话：010-56839300 根据《证券法》《证券发行上市保荐业务管理办法》和《上海证券交易所科 创板股票上市规则》等有关法律、法规的规定，华泰联合证券有限责任公司（以 下简称"华泰联合证券"或"保荐机构"）作为江苏集萃药康生物科技股份有限 公司（以下简称"药康生物"、"公司"或"发行人"）首次公开发行股票的保 荐机构，对药康生物进行持续督导，并出具本 2024 年半年度持续督导跟踪报告： 一、保荐机构和保荐代表人发现的问题及整改情况 保荐机构核查发现，由于受内外部因素影响，报告期内公司募集资金投资项 目实施进度存在晚于预期情形。 公司已于2022年年度报告、2023年半年度报告、2023年年度报告、2024年半 年度报告披露相关事项，保荐机构亦已于《关于江苏集萃药康生物科技股份有限 公司2022年度募集资金存放与实际使用情况的核查 ...

2024 年第一次临时股东大会参会须知 2024年第一次临时股东大会会议资料 公司代码：688046 公司简称：药康生物 江苏集萃药康生物科技股份有限公司 2024 年第一次临时股东大会会议资料 二〇二四年九月 1 | 2024 | 年第一次临时股东大会参会须知 3 | | --- | --- | | 2024 | 年第一次临时股东大会会议议程 5 | | 关于公司 | 2024 年半年度利润分配预案的议案 7 | 2024年第一次临时股东大会会议资料 尊敬的各位股东： 为维护投资者的合法权益，确保江苏集萃药康生物科技股份有限公司（以下 简称"公司"）2024 年第一次临时股东大会的顺利召开，依据中国证券监督管 理委员会《上市公司股东大会规则》等有关规定，制定会议须知如下： 一、公司根据《公司法》《证券法》《公司章程》及《股东大会议事规则》的 规定，认真履行法定职责，维护股东合法权益，做好召开股东大会的各项工作。 二、为保证股东大会的顺利召开，切实维护公司股东的合法权益，除出席会 议的股东，公司董事、监事、高级管理人员，公司聘请的律师及董事会邀请的人 员外，公司有权依法拒绝其他人员进入会场。 三、参会股东（含 ...

Investment Rating - Maintains a "Buy" rating with a target price of 11.41 yuan [5] Core Views - The company achieved revenue of 3.4 billion yuan in H1 2024, a YoY increase of 15.1%, driven by new domestic capacity and overseas market expansion [1] - Net profit attributable to shareholders was 763.38 million yuan, a slight YoY decrease of 1.6%, while non-GAAP net profit rose 10.7% YoY to 548.37 million yuan [1] - Q2 2024 revenue grew 17.8% YoY and 16.7% QoQ to 1.8 billion yuan, with net profit attributable to shareholders increasing 0.7% YoY and 59.0% QoQ to 468.58 million yuan [1] - Overseas market revenue reached 621.409 million yuan, a 44.9% YoY increase, accounting for 18.26% of total revenue [2] - The company is expected to achieve revenue growth of 23.04%, 23.01%, and 21.09% in 2024, 2025, and 2026, respectively, with net profit growth of 27.68%, 24.26%, and 23.41% [2] R&D and Product Development - The company continues to invest heavily in R&D, focusing on projects such as the "Wild Mouse Plan," "Germ-Free and Gnotobiotic Mouse Plan," "Spot Mouse Plan," and "Drug Screening Mouse Plan" [2] - Over 25 wild mouse strains have been launched, with more than 100 strains in the pipeline, expected to complete initial screening of 80-100 strains by 2024 [2] - The "Spot Mouse Plan" has completed over 20,000 strains, with more than 200 new strains added in the reporting period, covering research areas such as tumors, metabolism, and immunology [2] - The "Drug Screening Mouse Plan" has nearly 600 strains on the market, covering most reported druggable targets [2] Financial Projections - Revenue is projected to reach 7.6557 billion yuan in 2024, 9.4173 billion yuan in 2025, and 11.4037 billion yuan in 2026 [4] - Net profit attributable to shareholders is expected to be 2.029 billion yuan in 2024, 2.5211 billion yuan in 2025, and 3.1113 billion yuan in 2026 [4] - EPS is forecasted at 0.49 yuan, 0.61 yuan, and 0.76 yuan for 2024, 2025, and 2026, respectively [4] - ROE is expected to improve from 9.02% in 2024 to 11.55% in 2026 [4] Market Performance - The stock price has shown significant volatility over the past year, with a 45% decline at its lowest point and a 24% increase at its peak [6] - The current P/E ratio is 23.06x for 2024, expected to decrease to 15.04x by 2026 [4]

Investment Rating - The investment rating for the company is "Outperform the Market" [1][4][9]. Core Views - The company achieved a revenue of 340 million yuan in H1 2024, representing a year-on-year increase of 15.1%, primarily driven by the release of new domestic production capacity and expansion in overseas markets [1][5]. - The net profit attributable to the parent company was 76 million yuan, a decrease of 1.6% year-on-year, while the net profit excluding non-recurring items was 55 million yuan, an increase of 10.7% year-on-year [1][5]. - The overseas market revenue grew by 45% year-on-year, contributing to 18.3% of total revenue, with over 200 overseas clients served [1][8]. Summary by Sections Financial Performance - In Q1 2024, the company reported revenue of 157 million yuan (up 12.0% year-on-year) and in Q2 2024, revenue was 183 million yuan (up 17.8% year-on-year) [1][5]. - The company expects net profits for 2024, 2025, and 2026 to be 204 million, 259 million, and 297 million yuan respectively, with corresponding P/E ratios of 22, 17, and 15 times [1][9]. Market Expansion - The domestic market generated 278 million yuan in H1 2024, a 10.0% increase year-on-year, with nearly 2000 domestic clients served [1][8]. - The company has successfully expanded into high-potential cities such as Beijing, Tianjin, Wuhan, Changsha, and Zhengzhou, enhancing its market penetration [1][8]. Capacity Utilization - New facilities in Beijing, Shanghai, and Guangdong have been operational since the second half of 2023, with a total capacity of approximately 80,000 cages, leading to improved capacity utilization in H1 2024 [1][8]. - The first overseas facility in San Diego, USA, has been operational since Q1 2024, enhancing service capabilities for overseas clients [1][8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown steady growth in Q2 performance, with a significant increase in overseas expansion opportunities that are expected to drive future growth [4] - The company maintains a dual-driven business model of "products + services" and is actively developing new fields such as non-tumor models and wild-type mice, with rapid growth in overseas business [4][5] - The company is optimistic about its long-term development and maintains profit forecasts for 2024-2026, expecting net profits of 204 million, 251 million, and 319 million yuan respectively, with corresponding EPS of 0.50, 0.61, and 0.78 yuan [4] Financial Performance Summary - In H1 2024, the company achieved operating revenue of 340 million yuan, a year-on-year increase of 15.05%, and a net profit attributable to the parent company of 76.34 million yuan, a year-on-year decrease of 1.59% [4] - For Q2 alone, the company reported operating revenue of 183 million yuan, a year-on-year increase of 17.83% and a quarter-on-quarter increase of 16.68% [4] - The company’s net profit for Q2 was 46.86 million yuan, a year-on-year increase of 0.73% and a quarter-on-quarter increase of 58.95% [4] - The company’s revenue is expected to grow steadily, with projected revenues of 761 million, 953 million, and 1.197 billion yuan for 2024, 2025, and 2026 respectively, reflecting year-on-year growth rates of 22.3%, 25.2%, and 25.6% [7] Business Development - The company has proactively expanded its BD team, with nearly 100 members as of June 2024, serving around 2000 clients and adding nearly 400 new clients in H1 2024 [6] - The overseas market has shown significant growth, with revenue reaching 62.14 million yuan in 2023, a year-on-year increase of 44.91% [6] - The company has launched over 200 new high-value mouse strains in H1 2024 and is rapidly advancing its wild-type mouse project [5]

Investment Rating - The report maintains a "Recommended" rating for the company [4][5][10] Core Viewpoints - The company achieved a revenue of 340 million yuan in the first half of 2024, representing a year-on-year growth of 15.05%, while the net profit attributable to the parent company was 76 million yuan, a decrease of 1.59% [2] - The company plans to distribute a dividend of 0.30 yuan per 10 shares (including tax) [2] - The overseas market contributed significantly to growth, with revenue from international operations reaching 62 million yuan, an increase of 44.91%, accounting for 18.26% of total revenue [4][5] Financial Summary - Revenue projections for the upcoming years are as follows: 622 million yuan in 2023, 749 million yuan in 2024, 910 million yuan in 2025, and 1,116 million yuan in 2026, with year-on-year growth rates of 20.5%, 20.4%, 21.5%, and 22.6% respectively [3][9] - Net profit is expected to be 159 million yuan in 2023, 193 million yuan in 2024, 244 million yuan in 2025, and 303 million yuan in 2026, with year-on-year growth rates of -3.5%, 21.3%, 26.5%, and 24.2% respectively [3][9] - The gross margin for the first half of 2024 was 64.52%, a decrease of 3.97 percentage points due to competitive pricing adjustments [5] Growth Drivers - The company’s core revenue drivers include commercialized mouse models, which generated 200 million yuan in revenue, and customized breeding services, which brought in 43 million yuan [4] - The establishment of the first overseas facility in the United States is expected to enhance responsiveness and reliability in the supply chain, further accelerating market sales [5]